Batiraxcept

DRUG5 trials

Sponsors

M.D. Anderson Cancer Center, Aravive, Inc., Washington University School of Medicine

Conditions

Clear Cell Renal Cell CarcinomaPancreatic AdenocarcinomaPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPlatinum-resistant Ovarian CancerRecurrent Fallopian Tube CarcinomaRecurrent High Grade Uterine Cancer

Phase 1

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

TerminatedNCT04019288

M.D. Anderson Cancer CenterPlatinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma +6

Start: 2019-12-03End: 2024-10-24Updated: 2025-06-11

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

TerminatedNCT04300140

Aravive, Inc.Clear Cell Renal Cell Carcinoma

Start: 2021-02-26End: 2023-08-14Updated: 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

TerminatedNCT04983407

Aravive, Inc.Pancreatic Adenocarcinoma

Start: 2021-07-28End: 2023-08-14Updated: 2023-10-30

AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

WithdrawnNCT05826015

Washington University School of MedicineRecurrent High Grade Uterine Cancer

Start: 2024-10-31End: 2034-06-04Updated: 2024-10-02

Phase 3

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

TerminatedNCT04729608

Aravive, Inc.Platinum-resistant Ovarian Cancer

Start: 2021-04-22End: 2023-08-04Updated: 2023-10-30

Related Papers

Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma

The Oncologist2025-06-01

AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer.

Journal of Clinical Oncology2024-06-058 citations

Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer.

2024-04-233 citations

Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).

Journal of Clinical Oncology2023-06-016 citations

Phase 1b study of batiraxcept (AVB-S6-500, BT) plus gemcitabine (G) and nab-paclitaxel (NP) as first-line treatment (1L) for advanced pancreatic adenocarcinoma (PDAC).

Journal of Clinical Oncology2023-06-013 citations

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC).

Journal of Clinical Oncology2023-02-204 citations

Abstract CT506: Exposure-response analysis of batiraxcept and application to recommended phase 2 dose in platinum-resistant ovarian and clear cell renal cancers

Cancer Research2022-06-15

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140).

Journal of Clinical Oncology2022-06-0110 citations

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140).

Journal of Clinical Oncology2022-06-016 citations

424 A phase 1b/2 randomized study of AVB-S6–500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment

Regular and Young Investigator Award Abstracts2021-11-012 citations

A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004).

Journal of Clinical Oncology2021-05-201 citations